BRPI0308513B8 - micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém - Google Patents

micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém

Info

Publication number
BRPI0308513B8
BRPI0308513B8 BRPI0308513A BR0308513A BRPI0308513B8 BR PI0308513 B8 BRPI0308513 B8 BR PI0308513B8 BR PI0308513 A BRPI0308513 A BR PI0308513A BR 0308513 A BR0308513 A BR 0308513A BR PI0308513 B8 BRPI0308513 B8 BR PI0308513B8
Authority
BR
Brazil
Prior art keywords
preparation
inhalation
powder
tiotropium bromide
pharmaceutical composition
Prior art date
Application number
BRPI0308513A
Other languages
English (en)
Other versions
BR0308513A (pt
BRPI0308513B1 (pt
Inventor
Graebner Hagen
Bender Helmut
Schindler Konrad
Josef Friedrich Trunk Michael
Walz Michael
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27797948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0308513(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0308513A publication Critical patent/BR0308513A/pt
Publication of BRPI0308513B1 publication Critical patent/BRPI0308513B1/pt
Publication of BRPI0308513B8 publication Critical patent/BRPI0308513B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hybrid Cells (AREA)

Abstract

"micronizado cristalino de brometo de tiotrópio". a presente invenção refere-se a um micronisado cristalino de brometo de (1alfa, 2beta, 4beta, 5alfa, 7beta)-7-[(hidroxidi-2-tienilacetil)óxi]-9,9-dimetil-3-oxa-9-azoniatriciclo[3.3.1.0^ 2,4^]nonano, ao processo para sua preparação, bem como ao seu uso para preparação de um medicamento, particularmente para preparação de um medicamento com efeito anticolinérgico.
BRPI0308513A 2002-03-20 2003-03-10 micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém BRPI0308513B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10212264A DE10212264A1 (de) 2002-03-20 2002-03-20 Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
PCT/EP2003/002422 WO2003078429A1 (de) 2002-03-20 2003-03-10 Kristallines mikronisat des tiotropiumbromids

Publications (3)

Publication Number Publication Date
BR0308513A BR0308513A (pt) 2005-01-04
BRPI0308513B1 BRPI0308513B1 (pt) 2016-04-19
BRPI0308513B8 true BRPI0308513B8 (pt) 2021-05-25

Family

ID=27797948

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308513A BRPI0308513B8 (pt) 2002-03-20 2003-03-10 micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém

Country Status (37)

Country Link
EP (3) EP1785422B1 (pt)
JP (1) JP4331619B2 (pt)
KR (2) KR101021430B1 (pt)
CN (2) CN100368410C (pt)
AR (1) AR039017A1 (pt)
AT (1) ATE369365T1 (pt)
AU (1) AU2003212327B2 (pt)
BR (1) BRPI0308513B8 (pt)
CA (1) CA2479652C (pt)
CO (1) CO5611105A2 (pt)
CY (2) CY1106923T1 (pt)
DE (2) DE10212264A1 (pt)
DK (2) DK1785422T3 (pt)
EA (1) EA007064B1 (pt)
EC (1) ECSP045310A (pt)
ES (2) ES2291619T5 (pt)
HK (1) HK1078871A1 (pt)
HR (1) HRP20040855B1 (pt)
HU (1) HUE031876T2 (pt)
IL (2) IL163841A0 (pt)
LT (1) LT1785422T (pt)
ME (1) ME02764B (pt)
MX (1) MXPA04009056A (pt)
MY (1) MY139720A (pt)
NO (2) NO346754B1 (pt)
NZ (1) NZ535808A (pt)
PE (1) PE20030838A1 (pt)
PL (1) PL220730B1 (pt)
PT (2) PT1487832E (pt)
RS (1) RS57551B1 (pt)
SA (1) SA03240098B1 (pt)
SI (1) SI1487832T2 (pt)
TW (1) TWI345975B (pt)
UA (1) UA78295C2 (pt)
UY (1) UY27725A1 (pt)
WO (1) WO2003078429A1 (pt)
ZA (1) ZA200405636B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
PT1682541E (pt) 2003-11-03 2010-04-14 Boehringer Ingelheim Int Processo para a preparação de sais de tiotrópio
ES2422730T3 (es) 2003-11-03 2013-09-13 Boehringer Ingelheim Int Sales de tiotropio, procedimiento para su preparación, así como formulaciones de medicamentos que las contienen
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
EP2085396A3 (en) 2005-05-02 2009-11-25 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
CN101203513A (zh) * 2005-05-02 2008-06-18 贝林格尔·英格海姆国际有限公司 噻托溴铵的晶型
BRPI0614410A2 (pt) 2005-08-15 2011-03-29 Boehringer Ingelheim Int processo para preparação de betamiméticos
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
EP2123650B1 (en) 2005-12-19 2012-04-04 Sicor, Inc. Novel form of tiotropium bromide and process for preparation thereof
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2533765A2 (en) * 2010-01-29 2012-12-19 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
GEP201706672B (en) 2012-07-05 2017-05-25 Arven Ilac Sanayi Ve Ticaret As Dry powder inhaler compositions comprising long acting muscorinic antagonists
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
WO2014042605A1 (en) * 2012-09-11 2014-03-20 Mahmut Bilgic New tiotropium bromide crystalline form
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
HUE049339T2 (hu) 2014-09-09 2020-09-28 Vectura Ltd Glikopirrolátot tartalmazó készítmény, eljárás és berendezés
CA3002300A1 (en) * 2015-10-23 2017-04-27 Arven Ilac Sanayi Ve Ticaret A.S. Blister for inhalable formulation of tiotropium bromide
EP3159278A1 (en) * 2015-10-23 2017-04-26 Arven Ilac Sanayi Ve Ticaret A.S. Blister for tiotropium bromide inhalable formulation
CN115737610B (zh) * 2021-12-13 2024-02-27 苏州欧米尼医药有限公司 一种噻托溴铵吸入粉雾剂及其活性成分的气流粉碎方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
IE59026B1 (en) 1985-07-30 1993-12-15 Glaxo Group Ltd Devices for administering medicaments to patients
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19515625C2 (de) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern
FR2779347A1 (fr) * 1998-06-05 1999-12-03 Arlette Guerry Procede de micronisation de substances medicamenteuses
CN1150890C (zh) 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
WO2000064468A2 (en) † 1999-04-23 2000-11-02 Research Corporation Technologies Therapeutic compositions and methods for enhancing angiogenesis
WO2001026630A1 (fr) 1999-10-12 2001-04-19 Kaken Pharmaceutical Co., Ltd. Preparations pour inhalation en poudre et leur procede de production
EE04414B1 (et) 2000-10-12 2005-02-15 Boehringer Ingelheim Pharma Kg Tiotroopiumi sisaldav inhalatsioonipulber, meetodselle valmistamiseks ja selle kasutamine ravimi valmistamiseks
PL207870B1 (pl) 2000-10-12 2011-02-28 Boehringer Ingelheim Pharma Krystaliczny monohydrat bromku tiotropium, sposób jego wytwarzania, środek leczniczy i zastosowanie
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
PL208137B1 (pl) 2001-06-22 2011-03-31 Boehringer Ingelheim Pharma Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
AU2003276525A1 (en) 2002-11-15 2004-06-15 Orchid Chemicals And Pharmaceuticals Ltd Novel amorphous hydrate of a cephalosporin antibiotic
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
CN102127069A (zh) 2010-01-20 2011-07-20 鲁南制药集团股份有限公司 噻托溴铵晶体

Also Published As

Publication number Publication date
CY1106923T1 (el) 2012-09-26
NO20190824A1 (no) 2004-10-14
EP1785422B1 (de) 2016-11-16
EP1487832B2 (de) 2018-08-29
SA03240098B1 (ar) 2008-03-24
EP1487832B1 (de) 2007-08-08
IL163841A0 (en) 2005-12-18
SI1487832T1 (sl) 2007-12-31
CN101220025A (zh) 2008-07-16
DK1487832T4 (en) 2018-12-10
CO5611105A2 (es) 2006-02-28
LT1785422T (lt) 2017-02-10
UY27725A1 (es) 2003-10-31
ES2615460T3 (es) 2017-06-07
PT1487832E (pt) 2007-08-27
DE50307883D1 (de) 2007-09-20
PL371799A1 (en) 2005-06-27
UA78295C2 (en) 2007-03-15
JP2005526776A (ja) 2005-09-08
NO20044003L (no) 2004-10-14
TW200305421A (en) 2003-11-01
HK1078871A1 (en) 2006-03-24
AU2003212327A1 (en) 2003-09-29
KR20050008662A (ko) 2005-01-21
PE20030838A1 (es) 2003-11-21
CN1642952A (zh) 2005-07-20
TWI345975B (en) 2011-08-01
ES2291619T3 (es) 2008-03-01
EP3053921A1 (de) 2016-08-10
EP1487832A1 (de) 2004-12-22
HRP20040855B1 (en) 2012-11-30
PT1785422T (pt) 2017-02-17
HUE031876T2 (en) 2017-08-28
ECSP045310A (es) 2004-10-26
HRP20040855A2 (en) 2005-06-30
BR0308513A (pt) 2005-01-04
AU2003212327B2 (en) 2009-02-05
NZ535808A (en) 2005-09-30
CA2479652C (en) 2012-07-10
WO2003078429A1 (de) 2003-09-25
SI1487832T2 (sl) 2018-11-30
JP4331619B2 (ja) 2009-09-16
NO344427B1 (no) 2019-12-02
MY139720A (en) 2009-10-30
EP1785422A1 (de) 2007-05-16
EA200401142A1 (ru) 2005-04-28
KR101021430B1 (ko) 2011-03-15
EP1785422A8 (de) 2010-06-23
DK1785422T3 (en) 2017-02-27
MEP46708A (en) 2011-02-10
CN100368410C (zh) 2008-02-13
ES2291619T5 (es) 2018-12-07
DE10212264A1 (de) 2003-10-02
NO346754B1 (no) 2022-12-12
KR20100135983A (ko) 2010-12-27
ZA200405636B (en) 2006-01-25
EA007064B1 (ru) 2006-06-30
IL163841A (en) 2015-10-29
RS57551B1 (sr) 2018-10-31
EP1487832B9 (de) 2019-01-23
MXPA04009056A (es) 2005-01-25
ME02764B (me) 2011-05-10
ATE369365T1 (de) 2007-08-15
BRPI0308513B1 (pt) 2016-04-19
DK1487832T3 (da) 2007-11-05
PL220730B1 (pl) 2015-12-31
AR039017A1 (es) 2005-02-02
KR101094091B1 (ko) 2011-12-15
CY1118855T1 (el) 2018-01-10
CA2479652A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
BRPI0308513B8 (pt) micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém
BR0114584A (pt) Monohidrato cristalino, processos para a sua preparação e sua aplicação para a preparação de um medicamento
BR0210537A (pt) Anticolinérgico cristalino, processo para a sua preparação e sua aplicação para a preparação de um medicamento
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
BR0211284A (pt) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, a respectiva preparação e a respectiva aplicação em terapêutica
UY27751A1 (es) Método para la administración de un anticolinérgico por inhalación
BR0302965A (pt) Composto e método de tratar doenças mediadas por receptores de adenosina a2b
BR0207726A (pt) Sais farmacêuticos
BRPI0511136A (pt) formulações em pó para inalação contendo beta-agonistas enantiÈmeros puros
BRPI0608178A2 (pt) derivados de aminopirazol, sua fabricação, composição farmacêutica e uso como agentes farmacêuticos
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
BR0311896A (pt) Difenilazetidinonas substituìdas com grupos ácidos, processo para sua preparação, medicamentos contendo estes compostos e seu uso
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
BRPI0607614A2 (pt) sal de besilato da 7-(2-(4-3-trifluorometil-fenil)-1,2,3,6-tetrahidropirid- 1-il)etil) isoquinoleìna, o respectivo medicamento, composição farmacêutica e uso
BRPI0511999A (pt) compostos como antagonistas de ccr5
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
BRPI0304821B8 (pt) processo de preparação de uma suspensão estéril de partículas de corticosteróide para administração por inalação
BRPI0316908B8 (pt) preparo de suspensões aquosas estéreis incluindo ingredientes ativos cristalinos micronizados para inalação
BRPI0414780B8 (pt) composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto
BR0308592A (pt) Derivados de piperidina ou 8-azabiciclo [3.2.1] oct-3-il-piperidina, de utilidade como moduladores da atividade do receptor de quimocina (especialmente ccr5)
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
BRPI0413129A (pt) medicamentos para inalação compreendendo betamiméticos e anticolinérgico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/04/2016, OBSERVADAS AS CONDICOES LEGAIS.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTES DA NULIDADE: 1O)LIBBS FARMACEUTICA LTDA - PETICAO NO870160043523; 2O) ACHE LABORATORIOS FARMACEUTICOS S.A. - PETICAO NO870160060909.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 10/03/2023